Jonsson Comprehensive Cancer Center: New Treatment Extends Lives of People With Most Common Type of Liver Cancer
May 14, 2020
May 14, 2020
LOS ANGELES, California, May 14 -- The Jonsson Comprehensive Cancer Center at the University of California at Los Angeles issued the following news:
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
Researchers found that the combination of atezolizumab, an immunotherapy drug that boosts the body's natural defense . . .
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
Researchers found that the combination of atezolizumab, an immunotherapy drug that boosts the body's natural defense . . .